Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (Nasdaq: COO) announced that its Board appointed Colleen Jay as Chair, effective January 2, 2026, succeeding Robert Weiss, who will remain on the Board and stand for reelection for one final term.
The Board launched a formal strategic review of the company’s businesses, corporate structure, strategy, operations and capital allocation to identify opportunities to simplify the business and unlock long-term shareholder value, including partnerships, joint ventures, divestitures, mergers and other transactions. The company said it expects to focus capital deployment on repurchasing shares under its recently announced $2 billion share repurchase program.
CooperCompanies (Nasdaq: COO) reported fiscal Q4 2025 revenue of $1,065.2M (+5% reported, +3% organic) and fiscal 2025 revenue of $4,092.4M (+5% reported, +4% organic). Q4 GAAP diluted EPS was $0.43 (down 27%); fiscal 2025 GAAP EPS was $1.87 (down 4%). Q4 non-GAAP diluted EPS was $1.15 (+11%); fiscal 2025 non-GAAP EPS was $4.13 (+12%).
Q4 free cash flow was $149.8M; fiscal 2025 free cash flow was $433.7M. The company repurchased $197.3M of stock in Q4 and expanded its buyback authorization by $1B to $2B (about $1B remaining). Reorganization and integration activity generated ~$89M of charges with expected annual pre-tax savings of ~$50M beginning fiscal 2026.
Fiscal 2026 guidance: total revenue $4,299–$4,338M, non-GAAP EPS $4.45–$4.60, and free cash flow $575–$625M; long-term free cash flow objective of more than $2.2B for 2026–2028.
CooperCompanies (Nasdaq: COO) announced it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025 with a results release at 4:15 PM ET.
The company will host a conference call at 5:00 PM ET the same day to discuss results and corporate developments. Dial-in: 800-715-9871; conference ID: 2700541. A simultaneous audio webcast and subsequent replay will be available at http://investor.coopercos.com.
The Canadian Association of Optometrists (CAO) has launched a new digital awareness campaign during Children's Vision Month in October, focusing on children's vision care and the growing myopia epidemic. The campaign, supported by various optometry associations and industry sponsors including CooperVision (NYSE:COO) and Alcon, emphasizes that eye issues aren't always obvious.
The initiative promotes comprehensive eye exams starting at 6-9 months of age, with follow-ups between ages 2-5, and annually until age 19. The campaign highlights concerning statistics, including projections that myopia will affect 50% of the world's population by 2050. The campaign will run across multiple social media platforms in both English and French.
CooperCompanies (Nasdaq: COO) has announced a significant expansion of its share repurchase program, with the Board of Directors approving a $1 billion increase, bringing the total program to $2 billion.
CEO Al White emphasized that this decision reflects the company's strong balance sheet, robust cash flow generation, and the Board's confidence in Cooper's long-term growth prospects. The program will be executed through open market or private purchases, with timing and amount dependent on market conditions. The program has no expiration date but can be suspended or discontinued at any time.
CooperCompanies (Nasdaq: COO) reported Q3 2025 financial results with revenue increasing 6% year-over-year to $1.06 billion. CooperVision revenue grew 6% to $718.4 million, while CooperSurgical revenue rose 4% to $341.9 million.
The company's GAAP diluted EPS decreased 6% to $0.49, while non-GAAP diluted EPS increased 15% to $1.10. Despite revenues below expectations, Cooper raised its earnings guidance, projecting improved revenue in Q4 and fiscal 2026. The company generated strong margins and robust free cash flow of $164.6 million.
During Q3, Cooper repurchased $52.1 million of common stock at an average price of $71.97. The company updated its fiscal 2025 guidance, expecting total revenue of $4,076-$4,096 million with organic growth of 4-4.5%, and non-GAAP diluted EPS of $4.08-$4.12.
CooperCompanies (Nasdaq: COO), a leading global medical device company, has announced its participation in the upcoming Wells Fargo Healthcare Conference. President and CEO Al White will represent the company in a session scheduled for September 3, 2025, at 3:00 PM ET.
Investors and interested parties can access the webcast through CooperCompanies' investor relations website at http://investor.coopercos.com.
CooperCompanies (Nasdaq: COO), a leading medical device company, has scheduled its third quarter 2025 financial results announcement for August 27, 2025, at 4:15 PM ET.
The company will host a conference call at 5:00 PM ET to discuss results and corporate developments. Investors can join via phone at 800-715-9871 (Conference ID: 3665386) or access the audio webcast through the company's investor relations website.